Background: Central venous oxygen saturation (ScvO2) measurement is a safe and efficient alternative for mixed venous oxygen satu ration (SvO2) as an indirect estimate for global tissue oxygenation.The normal range of SvO2, which reflects the balance between O2 delivery and demands, is 65 to 75% Objectives: This study was designed to determine the predictive role of central venous oxygen saturation (ScvO2) in acute type I respiratory failure patients admitted to the pulmonary critical care unit.
Introduction
Measurement of venous oxygen saturation is an indirect way to determine global oxygenation. Venous oxygen saturation is an indirect index of global oxygen supply-todemand ratio (1).Central venous oxygen saturation (ScvO2) is the oxygen saturation of central venous blood. This value is obtained by placing a fiber-optic central venous catheter into the superior vena cava. ScvO2 reflects oxygen saturation of blood returning from the upper body and indicates the balance between oxygen delivery and oxygen consumption in the cranial portion of the body, including the brain (2).Mixed venous oxygen saturation (SvO2), on the other hand, is obtained from a pulmonary artery catheter and reflects overall SvO2 of blood returning from the upper body, the lower body, and the heart via the coronary sinus. Variations in regional blood flow from the upper body, lower body, and heart will affect the absolute values for ScvO2 and SvO2 (2) . Measurement of mixed venous oxygen saturation (SvO2) from the pulmonary artery has been advocated as an indirect index of tissue oxygenation (3). However, use of the pulmonary artery catheter has become somewhat unpopular (4,5). In contrast, insertion of a central venous catheter in the superior vena cava via the jugular or the subclavian vein is considered standard care in critically ill patients. Just like SvO2, the measurement of central venous oxygen saturation (ScvO2) has been advocated in order to detect global tissue hypoxia (6). The first sign that a patient is beginning to decompensate will be a decrease in ScvO2, prior to other hemodynamic or lab values changing. This early detection makes continuous ScvO2 an invaluable tool in the monitoring and treatment of the critically ill patient (7,8).SvO2 has been shown to have diagnostic, prognostic, and therapeutic use in the treatment of critically ill patients in the medical ICU and in septic shock. It has also been used in mechanically ventilated patients to determine the optimal level of positive end-expiratory pressure (PEEP) and to assist in weaning from mechanical ventilation (9,10).
Patients and methods
Clinical trial in which central venous oxygenation will be adopted as an index for tissue oxygenation in acute type I respiratory failure patients. The mortality will be considered as a primary end point. At the end, two groups will be present, dead and survived, each one will be control for the other. Acceptance of Ethical Committeewas gotten. This study was carried out on patients admitted to the pulmonary critical care unit (PCCU), chest department, Mansoura university hospitals during the period between August 2015 to December 2015.
Patients Inclusion criteria
All acute type I respiratory failure patients admitted to pulmonary critical care unit (PCCU), chest department, Mansoura university hospital. 
Patients Exclusion criteria

Methods
All patients were subjected to the following: 1. Through clinical history.
Through clinical examination: 3. Chest radiographs:
• Chest X-Rays. 
Laboratory investigations:
• Complete blood count including differential count.
• Complete metabolic profile (serum urea, serum creatinine, liver enzymes, serum albumin, serum total proteins, serum bilirubin, serum alkaline phosphatase, serum glucose, serum electrolytes (NA+, K+, Ca++).
• Sputum sample for bacterial culture and antibiotic sensitivity was taken from non-intubated patients and by sterile suction through the endotracheal tube in mechanically ventilated patients.
•
Nasopharyngeal swab for serological detection of Influenza A H1N1 virus in suspected cases. • Arterial blood gases. 6.Central venous catheter was inserted through a subclavian approach proceeded into the right atrium which was documented by post insertion CXR "the tip of the catheter being just at the lower border of the right 3 rd anterior rib at the right medial border of the sternum".
• Post-insertion portable CXR was taken as a guidance for repositioning of the catheter and for detection of postinsertion pneumothorax. • Central venous blood sample for central venous O2 saturation (ScvO2) will be taken on PCCU admission, 3 rd day and 7 th day after withdrawal of 20 ml blood to avoid the effect of frequent catheter flushing. Re-injection of withdrawed blood after sampling. 6. APACHE II scoring was adopted as a severity scoring on admission.
Statistical methods used for data analysis
Data were analyzed using STATA intercooled version 12.1. Quantitative data were represented as mean, standard deviation, median and range. We used student T-test when comparing the mean of survived versus dead groups. In nonparametric data Mann-Whitney test was used. Qualitative data were presented as number and percentage and compared using either Chi square test or fisher exact test. Receiver operating characteristic (ROC) curve was used to determine sensitivity, specificity, positive, and negative predictive value for different ScvO2 readings. The diagnostic accuracy of different variables was expressed as the area under the ROC curve (AUC). Graphs were produced by using Excel and/or STATA program. P value was considered significant if it was less than 0.05.
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Results
The study was conducted on patients admitted to the Pulmonary Critical Care Unit (PCCU), Mansoura University Hospitals with acute type I respiratory failure during the period between August 2015 and December 2015. After application of inclusion and exclusion criteria, 62 cases were included in this study. 
BMI: Body Mass Index
17 cases (27%) survived while 45 cases (73%) died.The mean age among living was 53 years (range 27-80) while in the mortality group was 62 years (range 17-90). The mean body mass index "BMI" among living was 23 (range 22-26) respectively while that in the mortality groupwas 24 (range 21-27).Mortality was high in non-smokers (60%) than ex-smokers (22%) and current smokers (18%). The mean ScvO2 on admission in survived patients was 72% while in dead patients it was 66%. At day 3, the mean ScvO2 in survived patients was 70% while in dead patients it was 64%. At day 7, the mean ScvO2 in survived patients was 74% while in dead patients it was 65%. There was a significant relation between ScvO2 values on admission and at the 3 rd and 7 th day and mortality (P value 0.009, 0.04 and 0.005 respectively). Abnormal ScvO2 on admission has significant relation to mortality (P value <0.0001). Low ScvO2 on admission was significantly related to mortality more than high admission ScvO2 (P value 0.001 and 0.42 respectively). Abnormal ScvO2 on day 3 has significant relation to mortality (P value <0.0001) Low ScvO2 on day 3 was significantly related to mortality more than high ScvO2 on day 3 (P value 0.001 and 0.71 respectively). 36 patients survived to day 7. Abnormal ScvO2 on day 7 has significant relation to mortality (P value 0.02). Low ScvO2 on day 7 was related to mortality more than high ScvO2 on day 7 (P value 0.03). 
Table (7): Comparison between change in ScvO2 between day 0 and day 3 and outcome
ScvO2: central venous oxygen saturation
There was a significant relation between deterioration of ScvO2 from day 0 to day 3 and mortality (P value 0.009).
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There was a significant relation between deterioration of ScvO2 from day 0 to day 7and mortality (P value 0.02). Regarding APACHE II score system, the cutoff point for predicting mortality was >27. It has a P value <0.0001. Regarding ScvO2 on admission, the cutoff point for predicting mortality was ≤65% has a P value 0.0008.Regarding ScvO2 at day 3, the cutoff point for predicting mortality was ≤70% has a P value 0.04. Regarding ScvO2 at day 7, the cutoff point for predicting 
Discussion
In our study we found that ScvO2 has a role in predicting mortality in patients admitted to the respiratory ICU with acute type I respiratory failure as initial abnormal ScvO2 was associated with increased risk of mortality in agreement with the results of Boulain et al., 2014 (11) who stated that initial low ScvO2 at ICU admission and persistent low ScvO2 values was independently associated with 28-day mortality and in contrast to results of Lee et al., 2016 (12)who stated that ScvO2 has some limitations as a predictor for outcome and that ScvO2 has no further prognostic value under lactate normalization after initial resuscitation. We found that mean ScvO2 on admission was 67% was comparable to 64% in results by Bracht et al., 2007 (13) and 70 % in results by Lee et al., 2016 (12) . We also found that ScvO2 on admission has a role in predicting mortality and that abnormal admission whether high or low was associated with increased risk of mortality (P value <0.0001) and that low initial ScvO2<65% was associated with increased risk of mortality (P value 0.001) agreeing with the results of Boulain et al., 2014 (11)who concluded that low initial ScvO2<70% was consistently linked to mortality (P value 0.0004). The mean ScvO2 on admission in survivors was 72% and in the mortality group was 66% with significant relation to mortality (P value 0.009) agreeing with results of Lee et al., 2016 (12) (72% and 69% respectively, P value 0.03). In our study, we found that persistently low ScvO2<65% at day 3 and day 7 can predict mortality in such critically ill patients (P value 0.001 and 0.03 respectively) agreeing with the results of Boulain et al., 2014 (11) who found that persistent low ScvO2<70% was associated with increased risk of mortality (P value 0.022) and with the results of Shin et al., 2016 (14) who found that persistent low ScvO2<70% was associated with increased risk of mortality (P value <0.01). We found that ScvO2>70% at day 3 and >66% at day 7 was associated with decreased risk of mortality agreeing with results of Rivers et al., 2001 (15) who reported that ScvO2>65% at day 3 was associated with decreased risk of mortality (P value <0.001). Normalization of ScvO2 from day 0 to day 3 and to day 7 is associated with decreased risk of mortality (P value 0.09 and 0.006 respectively). Also normalization o ScvO2 from day 0 to day 7 was associated with decreased risk of mortality (P value 0.02) in agreement with results of Rivers et al., 2001 (15) who found that attaining normal values of ScvO2 during resuscitation and in post resuscitative period was associated with decreased risk of mortality (P value 0.02). We calculated a cutoff point for ScvO2 on admission ≤65% to be associated with increased risk of mortality (P value 0.0008) where Boulain et al., 2014 (11) found that initial ScvO2<70% was associated with increased risk of mortality (P value 0.015) and Bracht et al., 2007 (13) who reported that low initial ScvO2 ≤60% was associated with increased risk of mortality (P value <0.05).We also calculated cutoff points for ScvO2 on day 3 ≤70% and on day 7 ≤66% that were associated with increased risk of mortality (P value 0.04 both) agreeing with results by Rivers et al., 2001 (15) who found that persistent low ScvO2<70% after 72 hours of ICU admission and thereafter was associated with increased risk of 28-day mortality (P value 0.02).We also found that failure of normalization of ScvO2 between day 0, day 3, day 3 to day 7 and day 0 to day 7 was associated with increased risk of mortality (P value 0.09, 0.006 and 0.02 respectively) agreeing with the results by Boulain et al., 2014 (11) who found that persistent low ScvO2 after ICU admission was associated with increased risk of 28-day mortality (P value 0.022).In our study we found that APACHE II score has a high significance in predicting mortality (P value 0.0003) agreeing with results of Shin et al., 2016 (14) and Lee et al., 2016 (12) who reported that APACHE II score was significantly related to mortality (P value <0.01 both). The mean APACHE II score of Hesham G. A. Ismail studied population was 23 in agreement with Romero et al., 2014 (16) and in contrast to Lee et al., 2016 (12) who reported a mean APACHE II score of 17. The mean APACHE II score for the survived group was 18 while that for the dead group was 25 (P value 0.0003) compared to results of Lee et al., 2016 (12) who found that the mean APACHE II score in the survived and mortality group was 16 and 23 respectively (P value <0.01). We calculated a cutoff point of >27 to be highly significant for predicting mortality (P value <0.0001) agreeing with results of Lee et al., 2016 (12) who found that APACHE II score >23 was associated with increased risk of mortality (P value <0.01).
Conclusion
Measuring ScvO2 on admission to the respiratory ICU has a strong role in predicting mortality in patients with acute type I respiratory failure as abnormal initial values for ScvO2 either high or low are associated with increased risk of mortality. Targeting normalization of abnormally high or low ScvO2 is associated with decreased risk of mortality.
Recommendation:
Recognition and treatment of the conditions leading to abnormal ScvO2 values should be started early before irreversible cellular damage occurs due to persistent cellular hypoxia. Maintaining normal values of ScvO2 should be aimed at the long term management of patients with acute type I respiratory failure patients after initial normalisation of ScvO2 during the first few hours of admission to the pulmonary critical care unit.
